MYD88 and diffuse large B-cell lymphoma: Mice bearing OCI-LY10 tumors (ABC DLBCL subtype, MYD88-L265P) were orally administered emavusertib either once daily at 25, 50, or 150 mg/kg, or twice daily at 12.5, 25, or 50 mg/kg for 14 consecutive days.